On 25 November, the World Health Organization updated its Guidelines for the Treatment of Malaria to include a 'strong recommendation' for pyronaridine-artesunate (Pyramax), a drug developed by MMV and Shin Poong Pharmaceutical.
The official inclusion of Pyramax into WHO’s Guidelines for malaria is a crucial step allowing malaria endemic countries to choose Pyramax as a first line ACT with confidence.
